Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today ...

The Task Force of the European Academy of Neurology and the Peripheral Nerve Society published updated guidelines in 2024 on the diagnosis and treatment of Guillain ... if the patient is unable ...

Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome ...

The Move GBS Forward campaign highlights a promising new approach to treatment of the disease. Annexon Biosciences CEO Doug ...

The technology has gradually helped Maynard get closer to her ultimate goal — reaching total independence and returning to ...

--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable ...

Guillain-Barré syndrome (GBS ... despite this therapy, some patients still make a slow or incomplete recovery. A recent study (Kuitwaard et al, 2009) aimed to examine whether pharmacokinetics ...

A Nottingham mechanic who was paralysed from the face down and had to sleep with his eyes open for three weeks has thanked ...

Because the headlines about measles focus on its dangers to children, one would think that children’s health is the topic ...

FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission Open-Label Tanruprubart FORWARD Study ...

BENGALURU: The Karnataka High Court appointed the wife of a retired man as his guardian to operate his three savings bank ...

A comprehensive new study reveals that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged ...